Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy

H. F. Hetta, K. Muhammad, A. M. Algammal, H. Ramadan, M. S. Abdel-Rahman, M. Mabrok, G. Koneru, A. A. Elkady, G. El-Saber Batiha, Y. Waheed, N. Munawar, H. S.M. Farghaly

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Angiotensin converting enzyme 2 (ACE2) has potentially conflicting roles in health and disease. COVID-19 coronavirus binds to human cells via ACE2 receptor, which is expressed on almost all body organs. Boosting the ACE2 receptor levels on heart and lung cells may provide more cellular enter to virus thereby worsening the infection. Therefore, among the drug targets, ACE2 is suggested as a vital target of COVID-19 therapy. This hypothesis is based on the protective role of the drugs acting on ACE2. Therefore, this review discusses the impact and challenges of using ACE2 as a target in the current therapy of COVID-19.

Original languageEnglish
Pages (from-to)3923-3932
Number of pages10
JournalEuropean review for medical and pharmacological sciences
Issue number10
Publication statusPublished - 2021


  • Angiotensin converting enzyme 2 (ACE2)
  • Azithromycin
  • COVID-19
  • Hydroxychloroquine
  • Vitamin D
  • Zinc

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy'. Together they form a unique fingerprint.

Cite this